

Australia and New Zealand Sarcoma Association (ANZSA)

Strategic Plan 2022-2024



TABLE OF CONTENTS

- 03** Message from the ANZSA Chair
- 04** Purpose and Vision
- 05** Quality Research and Clinical Care
- 09** Funding and Governance
- 12** Professional Education
- 15** Advocacy and Awareness

MESSAGE FROM THE ANZSA CHAIR

I am pleased to present the Australia and New Zealand Sarcoma Association (ANZSA) Strategic Plan 2022-2024.

This second strategic plan comes after successfully completing our Strategic Plan 2016-2021, which included 34 milestones. While we can be proud of our achievements, we know that there is much more to do to realise our vision and purpose.

The Strategic Plan 2022-2024 will continue to expand on the work we have embarked on that is driven by high-quality patient-centred clinical trials and research to improve patient survival rates and quality of life.

As the peak body for the sarcoma community, we will foster effective collaborations with international and local specialist health professionals to develop a universal and harmonised approach to sarcoma treatment and care.

Similarly, we will be a strong public advocate for patients, survivors and their families by working closely with consumer advocate representatives to communicate the importance of sarcoma awareness and fundraising.

As I look forward to an exciting journey ahead for the organisation, I am thankful to our collaborators, patients, donors and members for their continued support, generosity and trust in us and the work we do.

I commend this strategic plan and invite you to join us in supporting our vision and purpose.



Adrian Cosenza
Chair of ANZSA

PURPOSE

Improving outcomes for sarcoma patients.

VISION

To improve early diagnosis, treatment options, outcomes and quality of life of patients with sarcomas and related tumours through outstanding national and international, basic, translational, clinical and supportive care research and clinical trials operating to benchmarked best practice.

To be leaders in education and advocacy for sarcoma patients and professionals.

QUALITY RESEARCH AND CLINICAL CARE

Aims

- To improve patient survival rates and outcomes
- To build a strong research capability
- To deepen the portfolio of high-quality patient-centred clinical trials
- To enable patient recruitment to clinical trials
- To contribute to the development of a universal and harmonised approach to sarcoma treatment and care
- To improve and expand data collection and analytics
- To develop a sarcoma registry to world-class standards

QUALITY RESEARCH AND CLINICAL CARE

Milestones	Deliverables and Measures
<p>1) To identify potential national and international collaborations from the sarcoma research community.</p>	<ul style="list-style-type: none"> • Identify potential collaborations – End of 2023 • To maintain existing collaborations and implement one additional collaboration – End of 2024
<p>2) To increase ANZSA members' engagement and involvement in research studies and clinical trials.</p>	<ul style="list-style-type: none"> • Increase total membership to over 250 including 25 professional members - with particular focus on New Zealand – End of 2024 • Increase and expand Principle Investigators (PIs) and investigators on research studies and clinical trials – End of 2024 • Maintain database of research outcomes tied to ANZSA funding • Expand research portfolio with new areas of research (e.g. orthopaedic and patient-reported outcome (PRO))
<p>3) To develop a standard for sarcoma Centres of Excellence.</p>	<p>End of 2022</p>

QUALITY RESEARCH AND CLINICAL CARE

Milestones	Deliverables and Measures
<p>4) Implement standard for sarcoma Centres of Excellence.</p> <ul style="list-style-type: none"> • Develop and agree on criteria for ANZSA Centre of Excellence leads • Review Scientific Advisory Committee (SAC) Membership • SAC to create steering committee to determine work plan for Centres of Excellence • Identify potential Centres of Excellence • Nominate ANZSA Centre of Excellence leads in each sarcoma program 	<p>End of 2024</p> <p>End of 2024</p> <p>End of 2023</p> <p>Q3 of 2023</p> <p>End of 2023</p>
<p>5) To develop the Consumer Advisory Panel (CAP) to be a resource for researchers</p>	<ul style="list-style-type: none"> • Train consumers in research review – End of 2024 • Create a pool of trained consumer reviewers – End of 2024 • CAP to develop a mechanism for co-developed and consumer-driven research • Expand CAP membership (NZ and Indigenous representation)

QUALITY RESEARCH AND CLINICAL CARE

Milestones	Deliverables and Measures
6) To establish an ongoing program of sarcoma clinical care guidelines.	<p>By mid-2022</p> <p>Multi-disciplinary team (MDT) and retroperitoneal sarcoma (RPS) Guidelines to be published – End of 2022</p> <p>Determine next topics – End of 2022</p>
7) Explore the feasibility of adopting the Australian Orthopaedic Association National Joint Registry protocols to reflect sarcoma patient data.	<p>End of 2021</p> <p>Sarcoma surgeons to review</p>
8) Improve data quality from all sarcoma procedures (surgical and radiological) in the national sarcoma database.	<p>Determine gaps and decide on methodology – End of 2023</p> <p>Plan implemented – End of 2024</p>
9) Review accessible databases that can be leveraged.	<p>End of 2023</p>
10) Scope feasibility of sarcoma biobanking approaches to be aligned with database.	<p>End of 2023</p>
11) Determine feasibility of national Ewing sarcoma MDT.	<p>End of 2022</p>

FUNDING AND GOVERNANCE

Aims

- To deepen and further diversify funding sources
- To encourage philanthropic activity
- To increase government and peer-reviewed funding to sarcoma and related tumour research projects
- To achieve a sustainable long-term funding position
- To lead the application of contemporary governance practice, implementation of the Strategic Plan and prudent oversight of risk management
- To attract, develop and retain the best talent to work in sarcoma
- To recognise ANZSA members contributing to high-quality sarcoma and related tumour research
- To foster the next generation of sarcoma clinicians and researchers

FUNDING AND GOVERNANCE

Milestones	Deliverables and Measures
1) Identify potential industry funding partners.	End of 2021
2) To foster relationships with the sarcoma community to attract increased and reliable philanthropic funding.	End of 2024
3) To explore alternate funding models.	<ul style="list-style-type: none"> • Identify one new funding source beyond government and philanthropy • Determine if we charge for access to extracted data – End of 2022 • Explore if associated organisation membership fees (e.g. Cancer Cooperative Trials Groups, Clinical Oncology Society of Australia, etc.) is a possible model for funding – End of 2022
4) To develop a lobbying proposal for the government for funding of sarcoma.	Mid of 2022
5) To implement the agreed lobbying plan for funding of sarcoma.	End of 2024

FUNDING AND GOVERNANCE

Milestones	Deliverables and Measures
6) Create investment strategy and investment objectives.	Mid of 2022
7) Explore fundraising opportunities.	Decide fun run, merchandise, "Do the XX Sarcoma challenge" – End of 2022
8) Offer sarcoma research grants and Fellowship funding opportunities to build sarcoma research capacity.	<ul style="list-style-type: none"> • Offer at least one sarcoma research grant per year • Offer at least one Fellowship every other year
9) Encourage clinical trainees to contribute to ANZSA committees.	Ongoing until the end of 2024
10) Develop an annual recognition and award program.	End of 2022
11) To appoint a New Zealand representative to the SAC and the ANZSA Board.	November of 2022
12) To complete the ANZSA Board performance evaluation.	<ul style="list-style-type: none"> • To conduct an annual review of Board performance • Number of meetings attended • Peer evaluation of contribution by director
13) Maintain a long term succession plan for the Board.	Inventory of potential new board members to be reviewed annually by the ANZSA Board
14) Review ANZSA Board and committee memberships for skills matrix.	Review committee memberships to ensure required skills are at hand

PROFESSIONAL EDUCATION

Aims

- To foster the next generation of sarcoma clinicians and researchers
- To establish a framework for sarcoma professional education
- To encourage, welcome and promote active contribution from the orthopaedic sarcoma surgeon community
- To leverage the relationship with ISOLS and other educational bodies
- To promote sarcoma and related tumour research and clinical care to the clinical community
- To promote sarcoma guidelines and clinical care standards to the clinical community

PROFESSIONAL EDUCATION

Milestones	Deliverables and Measures
1) To create an Education Framework to include all education objectives.	End of 2023 Appoint Education sub-committee to have responsibility for driving these initiatives and scoping funding sources
2) To develop and deliver sarcoma education series.	Four per year
3) To embed the Sarcoma Journal Club in sarcoma clinician training.	Ongoing until the end of 2024
4) Encourage junior professionals to participate in sarcoma guidelines development.	Ongoing until the end of 2024
5) To hold an international meeting.	International Society of Limb Salvage (ISOLS) 2024

PROFESSIONAL EDUCATION

Milestones	Deliverables and Measures
6) To hold annual education day.	Professional education by specialty Set out rotation of presenters
7) Collaborate with other groups for education objectives and in particular orthopaedic sarcoma surgeons community within ANZSA (e.g. ANZGOG, ANZCHOG, VCCC, COSA, colleges).	Inventory of potential new board members to be reviewed annually by the ANZSA Board
8) Establish internship at ANZSA for students (not limited to medical, nursing and allied health).	Leverage University of Melbourne’s affiliation to attract limited internships for discrete projects – End of 2024
9) Collaborate with the orthopaedic surgeon community within ANZSA and the Australian Orthopaedic Association (AOA) on orthopaedic education curriculum.	End of 2024

ADVOCACY AND AWARENESS

Aims

- To promote sarcoma and tumour related research to the broader community
- To raise ANZSA's profile nationally and internationally
- To develop a closer engagement with the New Zealand sarcoma community
- To develop a closer relationship with the sarcoma orthopaedic surgeon community within ANZSA
- To cultivate influence internationally through the promotion of high-quality Australia and New Zealand sarcoma and tumour related research
- To be a strong public advocate for patients, survivors and their families
- To more purposefully advocate to government

ADVOCACY AND AWARENESS

Milestones	Deliverables and Measures
<p>1) To develop and implement an external and internal communication plan (2022-2024) including the international sarcoma community and other professional bodies (national and international).</p>	<p>Improvements in the awareness and communications dashboard metrics – End of 2024</p>
<p>2) To showcase quality sarcoma and related tumour research and activities to the sarcoma community (including ANZSA members, health professionals, consumers, and relevant international and national professional bodies).</p>	<ul style="list-style-type: none"> • End of 2024 • To communicate through ANZSA’s owned platforms such as Facebook, Instagram, LinkedIn, Twitter, newsletters, website and member notices. • Media releases – two per year (if applicable)
<p>3) To increase government awareness of ANZSA’s key role in sarcoma and related tumour research through a structured advocacy and lobbying program.</p>	<p>End of 2024</p> <p>As per milestone in funding and governance</p>

ADVOCACY AND AWARENESS

Milestones	Deliverables and Measures
4) To increase engagement frequency with New Zealand's sarcoma community (including MDT, health professionals and consumers).	Two meetings per year
5) CAP's objectives for patient education.	<ul style="list-style-type: none"> • Sarcoma awareness month each year (July) • Provide patient education resources
6) CAP's objectives for patient support and awareness.	Refer to Rare Cancers Australia for patient support services (and others as determined)
7) Conduct review of current advocacy landscape and determine where ANZSA should invest time for our initiatives and where we can foster collaborations.	<p>End of 2023</p> <p>Meet with Rare Cancers Australia to find collaboration opportunities</p>

